[
  {
    "ts": null,
    "headline": "Strategically Building A $10,000 Dividend Portfolio: Realty Income As Its Core Position",
    "summary": "Learn how holding Realty Income as the largest position in your $10,000 dividend portfolio can reduce risk and maximize income and growth. Read more here.",
    "url": "https://finnhub.io/api/news?id=ed5b1ad88b48698ab02323e38e598afc36fca5294cd6b1542bb9dcba902b651f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736445600,
      "headline": "Strategically Building A $10,000 Dividend Portfolio: Realty Income As Its Core Position",
      "id": 132354107,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1310768970/image_1310768970.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Learn how holding Realty Income as the largest position in your $10,000 dividend portfolio can reduce risk and maximize income and growth. Read more here.",
      "url": "https://finnhub.io/api/news?id=ed5b1ad88b48698ab02323e38e598afc36fca5294cd6b1542bb9dcba902b651f"
    }
  },
  {
    "ts": null,
    "headline": "Contineum concludes enrolment in Phase II multiple sclerosis therapy trial",
    "summary": "The trial is evaluating the efficacy and safety of PIPE-307 in RRMS patients.",
    "url": "https://finnhub.io/api/news?id=2ce3726f3e98b6b2d6e85d09d43de8c134b4195c4e1a03492dc1b9e022785690",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736442003,
      "headline": "Contineum concludes enrolment in Phase II multiple sclerosis therapy trial",
      "id": 132354177,
      "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/22/2025/01/shutterstock_2453832179-1.jpg",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The trial is evaluating the efficacy and safety of PIPE-307 in RRMS patients.",
      "url": "https://finnhub.io/api/news?id=2ce3726f3e98b6b2d6e85d09d43de8c134b4195c4e1a03492dc1b9e022785690"
    }
  },
  {
    "ts": null,
    "headline": "How to Find Strong Medical Stocks Slated for Positive Earnings Surprises",
    "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
    "url": "https://finnhub.io/api/news?id=a52fd56805147b03f9a26a00088eb61fc6a96b27b24339bd9c03578d00d0dd01",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736431213,
      "headline": "How to Find Strong Medical Stocks Slated for Positive Earnings Surprises",
      "id": 132354178,
      "image": "https://media.zenfs.com/en/zacks.com/39dfb058875b6e691de9136bc97a47b4",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
      "url": "https://finnhub.io/api/news?id=a52fd56805147b03f9a26a00088eb61fc6a96b27b24339bd9c03578d00d0dd01"
    }
  },
  {
    "ts": null,
    "headline": "J&J Pauses Sales of Atrial Fibrillation Device, Stock Down",
    "summary": "J&J's MedTech unit pauses all cases of the Varipulse PFA system as part of an external evaluation. Stock dips.",
    "url": "https://finnhub.io/api/news?id=dafcbc1711f31e1526350b7a6afdcf3e0fe9d2fe856f8c8baebde1ffe781afba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736429460,
      "headline": "J&J Pauses Sales of Atrial Fibrillation Device, Stock Down",
      "id": 132347873,
      "image": "https://media.zenfs.com/en/zacks.com/955c0f2ed0992898cedf76a9efa5b1f2",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "J&J's MedTech unit pauses all cases of the Varipulse PFA system as part of an external evaluation. Stock dips.",
      "url": "https://finnhub.io/api/news?id=dafcbc1711f31e1526350b7a6afdcf3e0fe9d2fe856f8c8baebde1ffe781afba"
    }
  },
  {
    "ts": null,
    "headline": "Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced the nipocalimab Biologics License Application (BLA) received Priority Review designation from the U.S Food and Drug Administration (FDA) for the treatment of antibody positive (anti-AChR, anti-MuSK, anti-LRP4) patients with generalized myasthenia gravis (gMG), as supported by findings from the Phase 3 Vivacity-MG3 study. The FDA grants Priority Review to applications for medicines that, if approved, would offer significant improvements in the safety",
    "url": "https://finnhub.io/api/news?id=27fa07e66074d80f69b7ba4f1015bae1ff8eb562f5e7d799691102a689c952eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736427840,
      "headline": "Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis",
      "id": 132354181,
      "image": "https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced the nipocalimab Biologics License Application (BLA) received Priority Review designation from the U.S Food and Drug Administration (FDA) for the treatment of antibody positive (anti-AChR, anti-MuSK, anti-LRP4) patients with generalized myasthenia gravis (gMG), as supported by findings from the Phase 3 Vivacity-MG3 study. The FDA grants Priority Review to applications for medicines that, if approved, would offer significant improvements in the safety",
      "url": "https://finnhub.io/api/news?id=27fa07e66074d80f69b7ba4f1015bae1ff8eb562f5e7d799691102a689c952eb"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson MedTech pauses Varipulse rollout in US",
    "summary": "Despite the pause, the company clarified that the suspension does not impact commercial activity outside the US.",
    "url": "https://finnhub.io/api/news?id=d8fec7651dc2909e7c0a8699547bd4fe44c96ab75e32c070838f5561568a56cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736423300,
      "headline": "Johnson & Johnson MedTech pauses Varipulse rollout in US",
      "id": 132354182,
      "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/23/2025/01/Johnson-Johnson-MedTech-pauses-Varipulse-rollout-in-US-_shutterstock_2028774359.jpg",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Despite the pause, the company clarified that the suspension does not impact commercial activity outside the US.",
      "url": "https://finnhub.io/api/news?id=d8fec7651dc2909e7c0a8699547bd4fe44c96ab75e32c070838f5561568a56cc"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Gets FDA Priority Review of Nipocalimab in Generalized Myasthenia Gravis",
    "summary": "By Colin Kellaher Johnson & Johnson has won Food and Drug Administration priority review for its application seeking approval of nipocalimab in certain patients with generalized myasthenia...",
    "url": "https://finnhub.io/api/news?id=3f3b4711439b25d97b205d3eec59b921331cbee3ea9c8eabda28c4a4d6ac6628",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736412192,
      "headline": "Johnson & Johnson Gets FDA Priority Review of Nipocalimab in Generalized Myasthenia Gravis",
      "id": 132347065,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Johnson & Johnson has won Food and Drug Administration priority review for its application seeking approval of nipocalimab in certain patients with generalized myasthenia...",
      "url": "https://finnhub.io/api/news?id=3f3b4711439b25d97b205d3eec59b921331cbee3ea9c8eabda28c4a4d6ac6628"
    }
  },
  {
    "ts": null,
    "headline": "J&J: FDA priority review for MGg",
    "summary": "Johnson & Johnson announced that the Biologics License Application for nipocalimab has received Priority Review designation from the U.S. Food and Drug Administration .This product is used for the...",
    "url": "https://finnhub.io/api/news?id=137565cae68726751c9a0afd7da570dcf584f58d4f9927528d8af06387204d8e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736411292,
      "headline": "J&J: FDA priority review for MGg",
      "id": 132347035,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson announced that the Biologics License Application for nipocalimab has received Priority Review designation from the U.S. Food and Drug Administration .This product is used for the...",
      "url": "https://finnhub.io/api/news?id=137565cae68726751c9a0afd7da570dcf584f58d4f9927528d8af06387204d8e"
    }
  },
  {
    "ts": null,
    "headline": "J&J: Fast Track status in early-onset Alzheimer's disease",
    "summary": "Johnson & Johnson announces that the FDA has granted 'Fast Track' designation to posdinemab , currently in phase 2b for the treatment of early-onset Alzheimer's disease. Posdinemab has demonstrated...",
    "url": "https://finnhub.io/api/news?id=354cdc8c75d336612c705c0c85269a8e5a6433aee747c5ee6ee34ea78057101c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736406013,
      "headline": "J&J: Fast Track status in early-onset Alzheimer's disease",
      "id": 132346565,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson announces that the FDA has granted 'Fast Track' designation to posdinemab , currently in phase 2b for the treatment of early-onset Alzheimer's disease. Posdinemab has demonstrated...",
      "url": "https://finnhub.io/api/news?id=354cdc8c75d336612c705c0c85269a8e5a6433aee747c5ee6ee34ea78057101c"
    }
  }
]